Hitachi Medical Systems Europe has announced separate collaborations with Medcom GmbH and Eigen USA to distribute the BiopSee® and Artemis from each respective company in conjunction with Hitachi's own systems. Both combined systems will be showcased at the European Association of Urology (EAU) annual meeting in Munich, March 12th-14 th, 2016, Booth #E16.
Hitachi Medical Systems Europe
+ + + P R E S S R E L E A S E + + +
Eigen USA and Hitachi Medical Systems Europe Switzerland announce a collaborative agreement for Hitachi to distribute the Artemis, Eigen’s robotic 3D targeted prostate biopsy device. The combined Hitachi Noblus and Artemis Eigen systems will be showcased at the European Association of Urology annual meeting in Munich, March 12th-14th, 2016, Booth #E16.
Switzerland, Zug, 11th of March, 2016 – Eigen, Grass Valley, California and Hitachi Medical Systems Europe announce a collaborative agreement for Hitachi to distribute the Artemis, Eigen’s robotic 3D targeted prostate biopsy device, through their subsidiaries’ sales network in Europe. In addition to co-marketing, both companies are collaborating to expand the versatility of Eigen’s Artemis and Hitachi Aloka’s suite of advanced ultrasound units, including their newest and most compact ultrasound unit yet, the Noblus.
ProFuse is now available as a standard part of Artemis, Eigen’s 3D ultrasound-guided prostate biopsy platform. The ProFuse line creates a synergy between the radiology lab and urology suite such that patients can benefit from this convergence.
The fusion of MRI and ultrasound is a time-saving and cost-effective alternative to in-bore biopsies. In relation to prostate cancer detection, multi-parametric MRI (mpMRI) has been shown to have greater sensitivity and specificity compared to traditional screening methods such as PSA. Using ProFuse to initially evaluate MRI images, radiologists can provide accurate mapping data about abnormalities, which can then be confirmed during a biopsy. During biopsy in the urology suite, Artemis with ProFuse Bx (elastic fusion component of Artemis) helps target the suspected lesions (identified in ProFuse) using its real-time ultrasound guidance.
Eigen and Hitachi are partnered together to provide the best solution for prostate cancer diagnosis and focal therapy planning: the combination of the Hitachi ultrasound system Noblus with Artemis promises to improve image quality during biopsy, providing more accurate diagnostic information that will result in better patient care, thus creating a new standard of care for customers and their patients. ‘We are very proud of this partnership with Eigen, and in combination with their advanced technology of the Artemis we can provide an important contribution to early disease detection, thus creating a new standard of care for customers and their patients and improving the health of our society’ , stated Mr. Chris Japp, President & CEO of Hitachi Medical Systems Europe.
Hitachi Medical Systems Europe are showcasing the combined Noblus and Artemis systems at the European Association of Urology annual meeting in Munich, March 12th-14th, 2016, Booth #E16.
In addition you can see & test both systems at the ESU/ESUT/ESUI Hands-on training in MRI Fusion, ICM building, Hall B0, level 0, Sunday, March 13th, 10.00-12.00 (HOT 29) and 14.00-16.00 (HOT 30).
- End of Press Release -
+ + + P R E S S R E L E A S E + + +
MedCom GmbH and Hitachi Medical Systems Europe announce an agreement to distribute BiopSee®, MedCom’s fusion imaging system for stereotactic, navigated, targeted prostate biopsy & therapy guidance, for use in conjunction with Hitachi ultrasound systems. The combined Hitachi Noblus and MedCom BiopSee® systems will be showcased at the European Association of Urology (EAU) annual meeting in Munich, March 12th-14 th, 2016, Booth #E16.
Switzerland, Zug, 11th of March 2016 – MedCom GmbH, Darmstadt, Germany and Hitachi Medical Systems Europe, Zug, Switzerland, announce an agreement to distribute through Hitachi’s subsidiaries sales network in Europe BiopSee®, MedCom’s fusion imaging system for stereotactic, navigated, targeted prostate biopsy & therapy guidance, for use in conjunction with Hitachi ultrasound systems. Hitachi will be the sole distributor of the BiopSee® products in this territory for Hitachi’s installed base and when bundled with Hitachi’s products.
BiopSee® fusion imaging station combines multi-parametric MRI with real-time ultrasound. It offers thereby exceptional precision in stereotactic and navigated interventions with intuitive workflow that can bring state-of-the-art technology to everyday urology practice. The BiopSee® software supports 3D ultrasound image acquisition, rigid/elastic fusion with MRI, planning, navigation, reporting of interventional procedures, and interfaces to focal therapy devices. An electronically tracked stepper provides millimetric precision for a transperineal approach, while a magnetically tracked freehand probe can be used for navigated TRUS and abdominal procedures.
The combined forces of the MedCom BiopSee® system, powered by urology’s Gold Standard ultrasound from Hitachi, offer “the best of both worlds” to medical practitioners and patients alike: the superior quality of Hitachi’s ultrasound with its wide variety of available transducers together with BiopSee’s® intuitive workflow, documentation and reporting, opening new possibilities for future patient management. ‘I am excited at the potential of this partnership to bring new and innovative clinical solutions to our customers’, said Mr. Chris Japp, President & CEO of Hitachi Medical Systems Europe.
The agreement allows Hitachi to respond rapidly to market needs providing flexible solutions for improved diagnostic and therapeutic image guidance in the field of prostate management.
Hitachi Medical Systems Europe are showcasing the combined Noblus and BiopSee® systems at the 2016 European Association of Urology annual meeting in Munich, March 12th-14th, 2016, Booth # E16. In addition you can see & test both systems at the ESU/ESUT/ESUI Hands-on training in MRI Fusion, ICM building, Hall B0, level 0, Sunday, March 13th, 10.00-12.00 (HOT 29) and 14.00-16.00 (HOT 30).
- End of Press Release -
About Hitachi Medical Systems Europe
Hitachi Medical Corporation is a globally acting enterprise, belonging to the Japanese Hitachi Ltd., a leading international electronics group with more than 320,000 employees worldwide. Hitachi Medical Corporation in Europe is represented by Hitachi Medical Systems Europe Holding AG, Zug, Switzerland. The company is a first choice supplier of open and powerful high-field MRI systems, multi-slice CT systems as well as medical ultrasound, endoscopic and topography systems (NIRS). Ultrasound expertise encompasses clinical applications such as radiology, internal medicine, obstetrics/gynaecology, cardiology, gastroenterology, urology and surgery. Hitachi Medical Systems Europe offers a complete range of solutions to address a wide range of medical challenges. For more information about Hitachi Medical Systems Europe Holding AG, please visit www.hitachi-medical-systems.eu
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges with our talented team and proven experience in global markets. The company is focusing more than ever on the Social Innovation Business, which includes power & infrastructure systems, information & telecommunication systems, construction machinery, high functional materials & components, automotive systems, healthcare and others. For more information about Hitachi Ltd., please visit http://www.hitachi.com/.
About Eigen
Eigen is a world leader in the development of innovative imaging devices and technology that today lets healthcare professionals improve their ability to visualize, diagnose and determine appropriate treatment pathways in over 4,000 hospitals worldwide. In particular, Eigen is the leader in MRI/US fusion technology for better prostate cancer detection, biopsy and focal therapy planning. For more information about Eigen, please visit http://www.eigen.com.
About MedCom
MedCom was founded in 1997 and is specialized in the field of medical imaging. MedCom offers innovative and advanced imaging-based products with emphasis on interventional/surgical navigation and cancer treatment solutions (instrument navigation, brachytherapy, patient positioning & verification, virtual simulation). MedCom developed the first commercially released “fusion imaging” & navigation product for liver (2002) and prostate (2007). As an OEM/B2B company, MedCom is providing products for various global corporations offering integrated clinical solutions, as well as to high-end clinics in the research sector. For more information about MedCom GmbH, please visit www.medcom-online.de.
11 March 2016
